Search | Clinical Trials Finder

Conditions: Edentulous Alveolar Ridge
Interventions: Gintuit, Bio-Gide; Biological · Device
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Orthopedic Disorder, Wound
Interventions: CAM; Biological
Lead sponsor: MED Institute Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Gulf Breeze, Florida • Voorhees Township, New Jersey

Conditions: Prostate Cancer
Interventions: Vitamin D3, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 19 Years to 90 Years · Male only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 2
States / cities: Charleston, South Carolina

Conditions: Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
Interventions: MRI-Guided Transurethral Ultrasound Ablation, Questionnaire Administration, Digital Rectal Examination, Cystoscopy, Biopsy, Bone Scan, PSMA PET Scan, Multiparametric Magnetic Resonance Imaging; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis
Interventions: methotrexate, methotrexate - etanercept - prednisolone arm; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 2 Years to 17 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 15
States / cities: Palo Alto, California • San Diego, California • San Francisco, California + 12 more

Conditions: Prostate Cancer
Interventions: DCFPyL PET/CT; Drug
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: 18 Years and older · Male only
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Irvine, California

Conditions: Vitamin D Deficiency
Interventions: Vitamin D3; Dietary Supplement
Lead sponsor: Tufts University; Other
Eligibility: 9 Years to 14 Years
Enrollment: 691 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy, no Evidence of Disease, Skin Cancer
Interventions: cholecalciferol; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 40 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Prostate Cancer
Interventions: PSMA ADC; Drug
Lead sponsor: Progenics Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 6
States / cities: Tucson, Arizona • New Orleans, Louisiana • Baltimore, Maryland + 3 more

Conditions: Atherosclerosis
Interventions: Vitamin D3; Dietary Supplement
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoarthritis, Knee
Interventions: Acellular amniotic membrane derived allograft injection (NuDYN); Drug
Lead sponsor: Illinois Center for Orthopaedic Research and Education; Other
Eligibility: 21 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Westmont, Illinois

Conditions: Foot Ulcer, Diabetic
Interventions: GrafixPRIME®, Dressing Application, Off-loading (walking boot); Other · Procedure · Device
Lead sponsor: Osiris Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Arizona City, Arizona • California City, California • New Mexico, New Mexico

Conditions: End Stage Renal Disease
Interventions: Standard dose, low flux hemodialysis, Standard dose, high flux hemodialysis, High dose, low flux hemodialysis, High dose, high flux hemodialysis; Device
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 1,846 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2001
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Congenital Pseudarthrosis of Tibia
Interventions: NVD003, Iliac Crest Bone Graft; Biological · Procedure
Lead sponsor: Novadip Biosciences; Industry
Eligibility: Up to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Phoenix, Arizona • Loma Linda, California • Baltimore, Maryland + 1 more

Conditions: Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
Interventions: Ipilimumab, Nivolumab; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Depression
Interventions: SSRI + LD, SSRI + PHD; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pressure Ulcer, Ulcer, Ulcer, Pressure, Pressure Injury
Interventions: ACApatch™, caregraFT™, Standard of Care; Other
Lead sponsor: Tiger Biosciences, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Monroeville, Pennsylvania

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Doxorubicin hydrochloride (liposomal); Drug
Lead sponsor: Sequus Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: TmPSMA-02; Biological
Lead sponsor: Tceleron Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Prostate Cancer
Interventions: Proxiscan device; Device
Lead sponsor: Radiological Associates of Sacramento Medical Group Inc.; Other
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Roseville, California

Conditions: Colorectal Cancer
Interventions: Immunochemical Fecal Occult Blood Test (I-FOBT) Kit, Standard Intervention (SI) Educational Materials, CARES Intervention Educational Materials, Baseline Visit Survey, Follow-up Questionnaire; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 50 Years to 75 Years
Enrollment: 514 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Advanced Age-related Macular Degeneration
Interventions: LFG316; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: Phoenix, Arizona • Beverly Hills, California • Fort Myers, Florida + 5 more

Conditions: Graft Versus Host Disease
Interventions: stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis), etanercept, methoxsalen; Procedure · Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: Not listed
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Chemotherapy-Induced Peripheral Neuropathy, Metastatic Breast Carcinoma
Interventions: Paclitaxel, Monosialotetrahexosylganglioside, Questionnaire Administration, Quality-of-life assessment, Placebo Administration; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 33
States / cities: Irvine, California • Orange, California • Clearwater, Florida + 26 more

Search by objective public record fields.

Safety Study of Gintuit™ in Subjects Requiring Socket Grafting

Registry of Amniotic Membrane: Evaluating Utilization and Outcomes in Various Applications

Vitamin D3 Supplementation for Low-Risk Prostate Cancer: A Randomized Trial

MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer

Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis

PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer

Impact of Vitamin D Supplementation on Cardiometabolic Risk Factors [The Daily D Health Study]

Vitamin D Levels in the Skin of Healthy Subjects After Oral Supplementation

An Open-label Extension Study of PSMA ADC 2301 in mCRPC

The Effect of Vitamin D Repletion on Small Low Density Lipoprotein (LDL) Particle Number in Subjects at Elevated Cardiovascular Risk

An Amniotic Membrane Injection Comparing Two Doses (1 mL and 2mL Injection) in the Treatment of Osteoarthritis of the Knee

GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers

Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis

A Study to Assess How Effective and Safe NVD003 is for Treating Patients With Congenital Pseudarthrosis of the Tibia.

Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer

Adding Exercise to Antidepressant Medication Treatment for Depression

Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers

Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.

A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Prostate Cancer Imaging With Radioactive Tracer and Ultrasound Detector Compared to MRI and ProstaScint

Colorectal Cancer Awareness, Research, Education and Screening (CARES)

Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant

Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)